Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. STOK
STOK logo

STOK Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Stoke Therapeutics Inc (STOK) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
33.020
1 Day change
1.82%
52 Week Range
40.220
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

STOK is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has some constructive technical strength and bullish-looking options flow, but there is no recent news catalyst, no strong proprietary buy signal, neutral insider/hedge fund activity, and no financial snapshot to support a confident long-term entry. Given the current price near short-term resistance and the lack of clear fundamental confirmation, the best call is to hold and wait for better confirmation rather than buy immediately.

Technical Analysis

The technical picture is moderately positive but not ideal for an immediate entry. MACD histogram is positive at 0.396, showing bullish momentum, though it is positively contracting, which suggests the upside momentum is not accelerating. RSI_6 is 76.253, which is elevated and points to stretched near-term conditions even though the provided interpretation labels it neutral. Moving averages are converging, which often signals an inflection area rather than a strong established trend. Price at 32.7 is just below R1 at 33.058 and above the pivot at 31.658, so the stock is trading near resistance instead of a clean breakout level. The pattern-based outlook also suggests a 70% chance of -1.11% next day, which makes the immediate risk/reward less attractive.

Options Data

Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio

Options sentiment is mixed but leaning bullish in positioning. The open interest put-call ratio of 0.72 is moderately bullish, indicating more call interest than puts on an open-interest basis. However, the option volume put-call ratio of 7.5 is very high and indicates much heavier put volume in the latest session, which can reflect short-term hedging or bearish speculation. Implied volatility at 70.26 is elevated versus historical volatility at 40.76, and today’s option volume is 383.87% of the 30-day average, showing unusually active trading. Overall, options data suggests heightened activity and disagreement, not a clean institutional buy signal.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
4
Buy
10

Positive Catalysts

  • ["No news in the recent week means there is no obvious negative event pressure.", "MACD remains above zero, which supports an underlying positive trend.", "Open interest put-call ratio of 0.72 suggests relatively constructive positioning.", "Swing and pre-market proprietary signals are absent, so there is no forced short-term sell signal from those systems."]

Neutral/Negative Catalysts

  • ["No recent news catalysts to drive a new long-term rerating.", "AI Stock Picker shows no signal today and SwingMax shows no recent signal.", "RSI is elevated, suggesting the stock may be extended in the near term.", "Price is near resistance at 33.058, limiting immediate upside.", "Insiders are neutral and hedge funds are neutral, so there is no strong accumulation signal.", "Option volume put-call ratio of 7.5 shows very bearish or hedging-heavy recent flow.", "No recent congress trading data is available.", "Stock pattern analysis implies a 70% chance of a slight decline next day."]

Financial Performance

No usable financial snapshot was provided, so latest quarter revenue or earnings growth cannot be confirmed. The latest quarter season is not available from the dataset. Because of that, there is no fundamental growth evidence here strong enough to support a beginner long-term buy decision.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target trend data was provided, so there is no visible Wall Street pros-versus-cons shift to report. Based on the available data, there is no evidence of a meaningful positive analyst revision trend, and no clear bullish consensus catalyst is visible.

Wall Street analysts forecast STOK stock price to rise
9 Analyst Rating
Wall Street analysts forecast STOK stock price to rise
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 32.430
sliders
Low
25
Averages
35.75
High
50
Current: 32.430
sliders
Low
25
Averages
35.75
High
50
Canaccord
NULL -> Buy
maintain
$36 -> $60
AI Analysis
2026-03-20
Reason
Canaccord
Price Target
$36 -> $60
AI Analysis
2026-03-20
maintain
NULL -> Buy
Reason
Canaccord raised the firm's price target on Stoke Therapeutics to $60 from $36 and keeps a Buy rating on the shares. The firm believes consensus is low as the company reiterated its timeline that it expects to complete enrollment on its ongoing Phase 3 EMPEROR trial for zorevunersen for Dravet syndrome in 2Q26, with data in mid-2027. The reason for the target increase is based on the new net price of $600k/year for zorevunersen.
Wedbush
Outperform
upgrade
$36 -> $38
2026-03-18
Reason
Wedbush
Price Target
$36 -> $38
2026-03-18
upgrade
Outperform
Reason
Wedbush raised the firm's price target on Stoke Therapeutics to $38 from $36 and keeps an Outperform rating on the shares. The firm notes the company has released their 10-K filing and while no separate press release was issued, all key objectives remain on track for the company. Most important in the near term remains the enrollment completion for the Phase 3 EMPEROR study of zorevunersen in Dravet Syndrome. Additionally, the recent publication of zorevunersen clinical data in NEJM reinforces Wedbush's view that the company is assembling a compelling data package for the drug with benefits on both seizure and non-seizure manifestations of disease.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for STOK
Unlock Now

People Also Watch